EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.2
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.85

18 Apr
2024

0.010

OPEN

$0.83

1.19%

HIGH

$0.86

66,920

LOW

$0.83

TARGET
$1.46 71.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 18.5 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 202120222023
EPS Basic xxxxxx-18.3
DPS All xxxxxx0.0
Sales/Revenue xxxxxx-
Book Value Per Share xxxxxx14.8
Net Operating Cash Flow xxxxxx-49.3 M
Net Profit Margin xxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023
Return on Capital Employed xxxxxx-95.69 %
Return on Invested Capital xxxxxx-52.18 %
Return on Assets xxxxxx-47.70 %
Return on Equity xxxxxx-95.69 %
Return on Total Capital xxxxxx-51.26 %
Free Cash Flow ex dividends xxxxxx-49.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023
Short-Term Debt xxxxxx0 M
Long Term Debt xxxxxx61 M
Total Debt xxxxxx61 M
Goodwill - Gross xxxxxx-
Cash & Equivalents - Generic xxxxxx106 M
Price To Book Value xxxxxx4.11

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023
Capex xxxxxx0.5 M
Capex % of Sales xxxxxx-
Cost of Goods Sold xxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxx51 M
Research & Development xxxxxx32 M
Investments - Total xxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

29/02/2024

1

Speculative Buy

$1.49

75.29%

FY23 results for EBR Systems were broadly in line with Morgans expectations. A net loss of -US$35m was greater than the  broker's --US$34m forecast, largely due to a US$3m increase in interest expense.

The analysts see around eight quarters of runway afforded by around US$73m of cash/short term investments on hand, given the current quarterly cash burn of circa -US$9.5m.

Management noted the design and verification testing schedule for the final Premarket Approval (PMA) module remains on track. A FDA filing should occur in the 3Q of 2024.

The Speculative Buy rating and $1.49 target are unchanged.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -18.42 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -16.75 cents.
Access Stockbroker Research History >

EBR STOCK CHART

FNArena News on EBR

1
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia
2
Australian Broker Call *Extra* Edition – Nov 23, 2023

Nov 23 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Sep 08, 2023

Sep 08 2023 - Daily Market Reports
4
FNArena Corporate Results Monitor – 30-08-2023

Aug 30 2023 - Australia
5
Australian Broker Call *Extra* Edition – Jul 06, 2023

Jul 06 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
2
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
3
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
4
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
5
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
6
ResMed Makes A Comeback

Jan 29 2024 - Australia
7
ResMed: The Recovery Has Begun

Jan 23 2024 - Technicals
8
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
9
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
10
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps